FOLD - Amicus Therapeutics, Inc.
After hours:
Chart Events
Short-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 12.62 |
| Open | 12.61 |
| Bid | 12.55 x 1300 |
| Ask | 13.00 x 1100 |
| Day's Range | 12.54 - 12.92 |
| 52 Week Range | 7.78 - 13.84 |
| Volume | |
| Avg. Volume | 2,519,941 |
| Market Cap | 3.645B |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.71 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.80 |
Fair Value
Related Research
ZacksWhy Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Simply Wall St.Amicus Therapeutics, Inc. (NASDAQ:FOLD): Is Breakeven Near?
We feel now is a pretty good time to analyse Amicus Therapeutics, Inc.'s ( NASDAQ:FOLD ) business as it appears the...
ZacksAmicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow
Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.
ZacksAmicus Therapeutics (FOLD) Reports Q1 Loss, Tops Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -38.46% and 5.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAmicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Complete; Approval Expected 3Q 2023 European Launch of Pombiliti®+Opfolda® Expected 3Q 2023 Non-GAAP Profitability Projected in 2H 2023 Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on develo
ZacksIcosavax, Inc. (ICVX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Icosavax, Inc. (ICVX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care Conference in Las Vegas, NV on Thursday, May 11, 2023, at 8:40 a.m. PT. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasda
ZacksWill Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2023. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a perso
- GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the European Union for the Treatment of Adults Living with Late-Onset Pompe Disease PHILADELPHIA, April 26, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion
- Simply Wall St.
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Popularity With Investors Is Under Threat From Overpricing
It's not a stretch to say that Amicus Therapeutics, Inc.'s ( NASDAQ:FOLD ) price-to-sales (or "P/S") ratio of 10.2x...
Barrons.comThe FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
ZacksAmicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease CHMP Opinion for Miglustat, the Oral Enzyme Stabilizer Component of AT-GAA, On-Track for 2Q 2023 PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has grant
Insider MonkeyAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics Full Year 2022 financial results conference call and webcast. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at […]
ZacksAmicus (FOLD) Q4 Earnings Miss, Galafold Sales Beat Estimates
Amicus (FOLD) posts a wider-than-expected fourth-quarter loss but strong sales of its solely marketed drug Galafold drive the top line.
- Thomson Reuters StreetEvents
Q4 2022 Amicus Therapeutics Inc Earnings Call
Q4 2022 Amicus Therapeutics Inc Earnings Call
ZacksAmicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
2022 Revenue Growth of 16% at CER to $329M Projecting Galafold Revenue Growth in 2023 of 12-17% at CER U.S. FDA Pre-approval Inspection for AT-GAA Now Scheduled; Approval expected in 3Q 2023 EU and U.K. AT-GAA Regulatory Reviews On-Track; Approvals expected in 3Q 2023 Non-GAAP Profitability Anticipated in 2H 2023 Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, March 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company f
- GlobeNewswire
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston, MA on Monday, March 6, 2023 at 9:50 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOL
- GlobeNewswire
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
Meaningful and Durable Responses in Key Endpoints of Six-Minute Walk, Forced Vital Capacity for ERT-Naïve and ERT-Experienced Participants Out to Two Years Consistent Reduction in Biomarkers Continue to Suggest a Positive Effect on Muscle Tissue; Including Participants who Switched from alglucosidase alfa to AT-GAA in the Open-label Extension Safety Profile Aligns with Previously Reported Data PHILADELPHIA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated
- GlobeNewswire
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
PHILADELPHIA, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, March 1, 2023 at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2022. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a perso
- GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
PHILADELPHIA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 11 posters across its development programs will be included at the 19th Annual WORLDSymposium™ 2023, being held February 22-26, 2023 in Orlando, FL. Oral Platform Presentation: Pompe Disease: Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02) Presenter: Barry Byr
- Simply Wall St.
Swelling losses haven't held back gains for Amicus Therapeutics (NASDAQ:FOLD) shareholders since they're up 39% over 1 year
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...
- GlobeNewswire
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
PHILADELPHIA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the SVB Securities Global Biopharma Conference, being held virtually, on Wednesday, February 15, 2023 at 10:40 a.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicus Therap